Shares of Marrone Bio Innovations Inc. (NASDAQ:MBII) have been given a consensus recommendation of “Hold” by the six brokerages that are covering the stock. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $5.50.
A number of research firms have commented on MBII. Jefferies Group raised their target price on shares of Marrone Bio Innovations from $1.50 to $2.50 and gave the stock a “hold” rating in a research note on Wednesday, November 23rd. Zacks Investment Research cut shares of Marrone Bio Innovations from a “hold” rating to a “sell” rating in a research note on Thursday, November 17th.
An institutional investor recently bought a new position in Marrone Bio Innovations stock. Ardsley Advisory Partners acquired a new position in shares of Marrone Bio Innovations Inc. (NASDAQ:MBII) during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 774,438 shares of the company’s stock, valued at approximately $1,324,000. Ardsley Advisory Partners owned approximately 3.15% of Marrone Bio Innovations as of its most recent SEC filing. 37.87% of the stock is currently owned by institutional investors and hedge funds.
Marrone Bio Innovations (NASDAQ:MBII) traded up 4.96% during trading on Monday, reaching $2.54. 220,561 shares of the company’s stock were exchanged. Marrone Bio Innovations has a 12-month low of $0.60 and a 12-month high of $2.79. The company’s market cap is $62.63 million. The stock’s 50-day moving average is $2.01 and its 200-day moving average is $1.31.
Marrone Bio Innovations (NASDAQ:MBII) last released its earnings results on Monday, November 14th. The company reported ($0.29) EPS for the quarter, missing analysts’ consensus estimates of ($0.22) by $0.07. Marrone Bio Innovations had a negative return on equity of 2,083.14% and a negative net margin of 258.51%. Analysts predict that Marrone Bio Innovations will post ($1.17) EPS for the current fiscal year.